Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Healthy Adults

In brief

The purpose of this study is to investigate the safety and efficacy of a gene therapy for Klotho, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of the Klotho gene therapy.

Key facts

Study ID

NCT07216781

Run by

Minicircle

People needed

24

Starts

2025-10-06

Expected to finish

2026-08-01

Last updated by the study team

2026-02-17

Who can join

Age: 23 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participant is open to morphological change
• If female, participant agrees to maintain contraception
• If female, participant agrees to take a pregnancy test
• If female, participant agrees to a pregnancy waiver

You may not qualify if…

• Women of childbearing potential who are unwilling or unable to use effective contraception for the duration of the study
• History of cancer diagnosis
• Preexisting medical issues that may be exacerbated by the treatment
• Has received any gene therapy within the past 12 months
• Unwilling or unable to provide written informed consent

Where it is running

• Apeiron Center — Austin, Texas, United States (enrolling)
• GARM Clinic — Roatán, Bay Islands, Honduras

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.